GLP-1 Drug Market to grow at a CAGR of 13.17% during 2025 to 2035; Driven by Rising Prevalence of Obesity and Diabetes and Increasing Adoption of GLP-1 Therapies

GLP 1 Drug Market Highlights

Global GLP-1 Drug Market Size was valued at USD 10.77 Billion in 2024 & the market is projected to grow from USD 12.19 Billion in 2025 to USD 42.0 Billion by 2035, registering a CAGR of 13.17% during 2025–2035.

The requirement for efficient treatments like GLP-1 receptor agonists is expanding because of the rising occurrence of diabetes around the world. Furthermore, a critical obstruction to the market extension of GLP-1 treatment is the accessibility of oral antidiabetic meds, which are frequently simpler to give than injectable GLP-1 drugs. Furthermore, the amazing chance to extend the signs for GLP-1 medications past diabetes to incorporate circumstances, for example, stoutness, non-alcoholic steatohepatitis (NASH), and cardiovascular illnesses, presents critical development potential. Moreover, Gastrointestinal adverse consequences like vomiting, nausea, and diarrhea related to GLP-1 medications can prompt poor patient compliance and therapy cessation.

MRFR recognizes the following companies as the key players in the global GLP-1 Drug market— Eli Lilly and Company, AstraZeneca, Pfizer, Sanofi, GSK, Novo Nordisk, Gan & Lee Pharmaceuticals, Boehringer Ingelheim, Tonghua Dongbao Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Shanghai Renhui Biopharmaceutical Co., Ltd., and Shanghai East China Pharmaceutical Machinery Co., Ltd.

Segment Analysis

The global GLP-1 Drug market has been segmented based on type and application.

Based on the type, the market is segmented into long-acting GLP-1 drugs and short-acting GLP-1 drugs. The long-acting GLP-1 drug segment was attributed to holding the largest market share in 2023. Long-acting GLP-1 medications can be joined with different classes of antidiabetic prescriptions, like insulin or SGLT-2 inhibitors, to accomplish synergistic impacts and further develop general glycemic control. This adaptability in treatment regimens improves their utility in overseeing type 2 diabetes.

Based on application, the global GLP-1 Drug market has been segmented into type 2 diabetes (T2DM), obesity, non-alcoholic steatohepatitis (NASH), Alzheimer's disease (AD), and cardiovascular and cerebrovascular diseases (CVD). In 2023, the type 2 diabetes (T2DM) segment was anticipated to have the highest market share. GLP-1 medications give an option in contrast to conventional insulin treatment, decreasing the requirement for different everyday infusions and working on drug regimens for patients with T2DM. This decrease in prescription weight can further develop treatment adherence and personal satisfaction.

Regional Analysis

Based on region, the global GLP-1 Drug market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European GLP-1 Drug market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The GLP-1 Drug market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's GLP-1 Drug market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share. Weight is a significant risk factor for type 2 diabetes, and North America has one of the greatest obesity rates in the world. As GLP-1 medications grow their signs to incorporate the control of obesity, the region presents a huge market potential because of the enormous populace impacted by weight-related conditions. Cardiovascular illness is a main source of morbidity and mortality in North America. GLP-1 medications with demonstrated cardiovascular advantages are strategically situated to address this basic well-being concern, driving interest and market development in the region.

Moreover, the European market has been persistently growing over the forecast period. European medical services frameworks frequently focus on non-insulin treatments for managing diabetes because of their great security profiles and decreased chance of hypoglycemia. GLP-1 medications, with their adequacy and cardiovascular advantages, adjust well to this inclination, driving adoption and market development.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. Governments across Asia Pacific are implementing different medical service changes and drives to address the rising weight of chronic sicknesses, including diabetes. This involves activities to increase accessibility to necessary prescription drugs and encourage preventative healthcare practices, which presents potential for producers of GLP-1 drugs.

Furthermore, the rest of the world's GLP-1 Drug market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising rates of obesity. Increasing Indications, Diabetes Prevalence, and the Development of Healthcare Infrastructure are all factors contributing to the market growth.

Key Findings of the Study

• North America led the Contract Research Organization (CRO) Market, accounting for over 44.96% of global revenue in 2024.


• Europe Contract Research Organization (CRO) Market was valued at USD 21.075 billion in 2024, remaining the second-largest regional market.


• Clinical trials accounted for approximately 68% of application revenue, reflecting sustained pharmaceutical outsourcing and increasing global clinical research activity.


• Pharmaceutical companies contributed nearly 64% of end-use demand, driven by expanding R&D investment and growing dependence on outsourced development services.